August 15, 2006 -- Shire settled its longstanding ADHD patent dispute with Barr; Lilly and Amylin said their Byetta cartridge shortage has ended; Genzyme touted results on tolevamer, its non-antibiotic diarrhea treatment; Emergent BioSolutions filed for to raise $86 million in an IPO; ActivBiotics will also seek to become a public company; Bio-Rad paid $20 million in cash for a protein analysis tool from Ciphergen; Akzo Nobel will separate its drug business into a separate entity and sell a 20% to 30% stake; Enzo reported its StealthVector HGTV43 gene medication was promising in early tests; and Biogen Idec disclosed the discovery of a new inflammation pathway in rheumatoid arthritis patients. The Centient Biotech 200™ rose 49 points to 3633.07, an increase of 1.38%. More details...
